Albendazole in hydatid disease.

Dl, Morris; Dykes, P. W.; Dickson, Brian; Marriner, S. E.; Bogan, J. A.; Burrows, F. A.

doi:10.1136/bmj.286.6359.103-a

Cited by 144 publications

(58 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…a showing lytic hydatid lesion of right ileum (arrow) before operation/chemotherapy. b 3 years later, after surgery and 6 courses of albendazole therapy is better absorbed with higher levels of active metabolite in the cysts compared with other benzimidazoles [10]. The poorest response has, however, been in hydatid disease of bone, although Szypryt et al have reported 5 patients treated successfully by a combination of albendazole and surgery, even though only one or two cycles of chemotherapy were given [20].…”

Section: Discussionmentioning

confidence: 99%

Albendazole treatment and serological follow-up in hydatid disease of bone

Bonifacino¹,

Dogliani²,

Craig

1997

International Orthopaedics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Albendazole treatment and serological follow-up in hydatid disease of bone

Bonifacino¹,

Dogliani²,

Craig

1997

International Orthopaedics

View full text Add to dashboard Cite

“…11 With albendazole therapy for cystic echinococcosis (CE) it cluded one case each of mild elevation of serum transaminase level and of alopecia. Cholestasis during or after chemotherhas been reported that approximately 33% of liver cysts became undetectable after treatment.…”

Section: 18mentioning

confidence: 99%

Effect of albendazole on recurrent and residual alveolar echinococcosis of the liver after surgery

et al. 1997

View full text Add to dashboard Cite

palliative operations such as marsupialization with biliary drainage, Patients with alveolar echinococcosis of the liverand laparotomy were performed in 14, 5, and 1 cases, respectively.(AEL) can be cured by complete excision of the lesions;Mebendazole had been given before albendazole therapy in 9 cases. however, it is not always completely resectable in ad-Eight patients had lung metastasis, and 2 had lymph node metastavanced cases. Recently, benzimidazole-type drugs have sis. The staging system proposed by Nakajima et al. 10 was used.been reported to be effective in nonresectable AEL. One Five groups (I, II, IIIa, IIIb, and IV) are obtained according to three hundred fifty-two patients with AEL have been surgi-principal degrees of anatomic extent: apparent localization of the cally treated in our institution since 1937. Our clinical site of origin (occupied segments); evidence of regional spread to the adjacent tissue or organ, usually in the form of direct invasion; and trial with albendazole, one of the benzimidazole carba- A IIIb indicates, in addition to involvement of one to three segments, favorable response to albendazole, such as decreases in regional tissue or organ invasion and/or distant metastasis, but all the size of the lesions, changes in cyst morphology, and lesions should be resectable. Stage IV indicates intrahepatic lesions amelioration in clinical symptoms or signs, was achieved occupied in four segments and/or regional invasion and/or distant in 11 (55%) cases. These favorable responses were also metastasis of which every lesion is nonresectable (i.e., curative operation cannot be achieved).10 Advanced stages were seen frequently; seen in cases of noncurative resection and palliative opthere were 1, 3, 4, 6, and 12 cases in stages I, II, IIIa, IIIb, and IV, eration. The cumulative survival rate of the patients was respectively. 87%, 15 years after the operation. A complete responseHematological examination and liver function tests were perwas achieved in one case; the residual lesion in the liver formed every 2 weeks, and serological tests and ultrasound (US) and completely disappeared on the computed tomography computed tomography (CT) scans were carried out at approximately image 3.5 years after noncurative surgery. Palliative or 6-month intervals. The drug protocol for albendazole (200-mg tablets; mass reduction surgery combined with albendazole obtained from SmithKline Beecham, Tokyo, Japan) was 10 mg/kg/d therapy may be a strategy for advanced disease, espe-orally in a treatment cycle of 4 weeks with 2-week breaks.3 This cycle cially when complete resection might result in signifi-was repeated indefinitely unless there were adverse reactions. The average duration of treatment was 3.25 years. cant morbidity or mortality. (HEPATOLOGY 1997;25:The study protocol of chemotherapy was approved by the ethics 528-531.)committee of the Department of Medicine of Hokkaido University. Chemotherapy was performed in patients after their informed conPatients with alveolar echinococcosis of the live...

show abstract

“…In the early 1970s, some benzoimidazole carbamates were proved to be effective against Echinococcus granulosus and, since then, many investigators have employed mebendazole and albendazole for the treatment of human hydatid disease (4,8,14,20,21,24,27,28,31). These drugs inhibit tubulin and induce blockage of glucose absorption, glycogen depletion, and degenerative alterations in the endoplasmic reticulum and mitochondria of the germinal layer, increasing lysosomes and producing cellular autolysis (6,13,18,20,32).…”

mentioning

confidence: 99%

Therapy of human hydatid disease with mebendazole and albendazole

Teggi

Lastilla

Rosa

1993

Antimicrob Agents Chemother

208

153

View full text Add to dashboard Cite

We report our experience in the treatment with benzoimidazole carbamates (mebendazole and albendazole) of 337 patients affected by hydatid cysts with different localizations. The treated cysts showed degenerative modifications in 50.6% of the cases after mebendazole treatment and in about 80%o after albendazole treatment. Relapses after therapy were observed in 30%o of the cases; about 95% of the recurring cysts showed good susceptibility to a further cycle of therapy with benzoimidazole carbamates. Side effects observed with either drug were not severe and always reversible, consisting mainly of abdominal pains and increased levels of transaminases in serum. Among the factors that may influence the therapeutic results are the drug employed, the age of the cysts, the age of the patient, and the localization of the cysts and their morphological characteristics. Moreover, it can be hypothesized that each hydatid cyst has an intrinsic sensitivity to benzoimidazole carbamates.

show abstract

Albendazole in hydatid disease.

Cited by 144 publications

References 4 publications

Albendazole treatment and serological follow-up in hydatid disease of bone

Albendazole treatment and serological follow-up in hydatid disease of bone

Effect of albendazole on recurrent and residual alveolar echinococcosis of the liver after surgery

Therapy of human hydatid disease with mebendazole and albendazole

Contact Info

Product

Resources

About